Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2025 16:03 ET | Source: Folia Health

Folia Health Expands Its Rare Renal Disease Research with a New C3G Study to Assess Real-World Disease Impact

BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Folia Health launches enrollment for an innovative, at-home real-world evidence initiative for individuals with C3 glomerulopathy (C3G). Designed in...
November 15, 2024 13:15 ET | Source: Spherix Global Insights

Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission

EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
June 13, 2024 11:39 ET | Source: Spherix Global Insights

Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment

EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
November 06, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch - Novartis, Apellis, NovelMed, Amyndas, Arrowhead

New York, USA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch - Novartis, Apellis,...
February 09, 2018 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
December 20, 2017 12:12 ET | Source: Achillion Pharmaceuticals, Inc.

CORRECTION - Achillion Pharmaceuticals, Inc.

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
December 20, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D

NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
November 01, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs

NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
October 24, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
August 08, 2017 16:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor

- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN -...

Next Page keyboard_arrow_right